Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Market for Insomnia Treatments to Expand to US$1 Bil. by 2019 in Japan: Datamonitor
August 16, 2010
- Taiyo Yakuhin Posts Measures to Improve Manufacturing Practice on Its Website
August 16, 2010
- Eisai: Sales Up 5% Driven by Good Sales of Aricept
August 16, 2010
- Seikagaku: Sales Remain Virtually Unchanged
August 16, 2010
- Sales of Ethical Drugs Up 2.3% in June: Crecon Report
August 16, 2010
- ARQ 197 to Enter PIII for NSCLC: Daiichi Sankyo, ArQule
August 16, 2010
- MTPC: Sales, Profits Up despite Biz Suspension
August 16, 2010
- JCR Pharmaceuticals: Upfront Payment from GSK Boosts Sales
August 16, 2010
- Market for Antidepressants in Japan Part II (1)
August 16, 2010
- SSP to Place Top Priority on Profit Ratio: President Shiono
August 16, 2010
- DSP: Former Sepracor Boosts Sales by 54.1%
August 16, 2010
- Wakamoto: Net Loss Increases to ¥132 Mil.
August 16, 2010
- Market for Antidepressants in Japan Part II (2)
August 16, 2010
- Daiichi Sankyo Aims to Enter Vaccine Market in Emerging Countries
August 16, 2010
- Shionogi: Crestor Pulls Up Sales 17.5%
August 16, 2010
- Medipal HD: Sales up 4.7% with Strong Increases in Profits
August 16, 2010
- 5 APIs, 7 Indications to Be Applied for Based on Data from Public Domain
August 16, 2010
- Taisho: Self-Medication Makes Up for Slump of Ethical Drugs
August 16, 2010
- Alfresa: Profits Up as a Result of Firm Pricing Policy
August 16, 2010
- Korosho Posts Its Policy for Assessment of Research Projects
August 16, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…